Proenergetic effects of resveratrol in the murine neuronal cell line neuro2a

Molecular Nutrition and Food Research

Volumn 57, Issue 11, 2013, Pages 1901-1907

  Nguyen, Nhu T Q ^a   Ooi, Lezanne ^b   Piller, Sabine C ^a   Münch, Gerald ^a  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

^b UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Energy levels; Neuronal cell line; Polyphenols

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIOXIDANT; FATTY ACID; GLUCOSE; GLUCOSE TRANSPORTER 4; GUANOSINE TRIPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LACTIC ACID; POLYPHENOL; RESVERATROL; STILBENE DERIVATIVE;

ANIMAL; ARTICLE; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; ENERGY LEVELS; ENERGY METABOLISM; GENETICS; METABOLISM; MOUSE; NERVE CELL; NEURONAL CELL LINE;

ENERGY LEVELS; NEURONAL CELL LINE; POLYPHENOLS;

ADENOSINE TRIPHOSPHATE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIOXIDANTS; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENERGY METABOLISM; FATTY ACIDS; GLUCOSE; GLUCOSE TRANSPORTER TYPE 4; GUANOSINE TRIPHOSPHATE; LACTIC ACID; MICE; NEURONS; STILBENES;

EID: 84886798197     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201300145     Document Type: Article

References (21)

1. Terry, R. D., Davies, P., Dementia of the Alzheimer type. Annu. Rev. Neurosci. 1980, 3, 77-95.
2. Mosconi, L., Brys, M., Glodzik-Sobanska, L., De Santi, S. et al., Early detection of Alzheimer's disease using neuroimaging. Exp. Gerontol. 2007, 42, 129-138.
3. Haxby, J. V., Grady, C. L., Duara, R., Schlageter, N. et al., Neocortical metabolic abnormalities precede nonmemory cognitive defects in early Alzheimer's-type dementia. Arch. Neurol. 1986, 43, 882-885.
4. Sakamoto, S., Ishii, K., Sasaki, M., Hosaka, K. et al., Differences in cerebral metabolic impairment between early and late onset types of Alzheimer's disease. J. Neurol. Sci. 2002, 200, 27-32.
5. Hoyer, S., Oxidative energy metabolism in Alzheimer brain. Studies in early-onset and late-onset cases. Mol. Chem. Neuropathol. 1992, 16, 207-224.
6. Sims, N. R., Bowen, D. M., Neary, D., Davison, A. N., Metabolic processes in Alzheimer's disease: adenine nucleotide content and production of 14CO2 from [U-14C]glucose in vitro in human neocortex. J. Neurochem. 1983, 41, 1329-1334.
7. Fogarty, S., Hardie, D. G., Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim. Biophys. Acta 2010, 1804, 581-591.
8. Leonard, S. S., Xia, C., Jiang, B. H., Stinefelt, B. et al., Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem. Biophys. Res. Commun. 2003, 309, 1017-1026.
9. Dasgupta, B., Milbrandt, J., Resveratrol stimulates AMP kinase activity in neurons. Proc. Natl. Acad. Sci. USA 2007, 104, 7217-7222.
10. Vingtdeux, V., Giliberto, L., Zhao, H., Chandakkar, P. et al., AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J. Biol. Chem. 2010, 285, 9100-9113.
11. Giannattasio, S., Gagliardi, S., Samaja, M., Marra, E., Simultaneous determination of purine nucleotides, their metabolites and beta-nicotinamide adenine dinucleotide in cerebellar granule cells by ion-pair high performance liquid chromatography. Brain Res. Brain Res. Protoc. 2003, 10, 168-174.
12. Peterson, J. I., Young, D. S., Evaluation of the hexokinase-glucose-6-phosphate dehydrogenase method of determination of glucose in urine. Anal. Biochem. 1968, 23, 301-316.
13. Rosenberg, J. C., Rush, B. F., An enzymatic-spectrophotometric determination of pyruvic and lactic acid in blood. Methodologic aspects. Clin. Chem. 1966, 12, 299-307.
14. Yang, M. S., Gupta, R. C., Determination of energy charge potential in the C6 glioma and the HepG-2 cell culture. Toxicol. Mech. Methods 2003, 13, 97-101.
15. Dasgupta, B., Milbrandt, J., Resveratrol stimulates AMP kinase activity in neurons. Proc. Natl. Acad. Sci. USA 2007, 104, 7217-7222.
16. Boocock, D. J., Faust, G. E., Patel, K. R., Schinas, A. M. et al., Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev. 2007, 16, 1246-1252.
17. Vlassenko, A. G., Vaishnavi, S. N., Couture, L., Sacco, D. et al., Spatial correlation between brain aerobic glycolysis and amyloid-beta (Abeta) deposition. Proc. Natl. Acad. Sci. USA 2010, 107, 17763-17767.
18. Vlassenko, A. G., Benzinger, T. L., Morris, J. C., PET amyloid-beta imaging in preclinical Alzheimer's disease. Biochim. Biophys. Acta 2012, 1822, 370-379.
19. Mihaylova, M. M., Shaw, R. J., The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell. Biol. 2011, 13, 1016-1023.
20. Zhou, R., Fukui, M., Choi, H. J., Zhu, B. T., Induction of a reversible, non-cytotoxic S-phase delay by resveratrol: implications for a mechanism of lifespan prolongation and cancer protection. Br. J. Pharmacol. 2009, 158, 462-474.
21. Joe, A. K., Liu, H., Suzui, M., Vural, M. E. et al., Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin. Cancer Res. 2002, 8, 893-903.